🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in South Korea / NCT06993168
Starting soon Phase 1

To Evaluate Effect of Food of DA-5222 in Healthy Adult Subjects

NCT06993168 · tracked via the Priya Life Science South Korea tracker
Phase
Phase 1
Started
2025-05-21
Last updated
2025-05-28

Condition(s) studied

Healthy

Investigational drug(s) / intervention(s)

DA-5222 →

DA-5222: single dose administration (DA-5222 one tablet once a day)

Study summary

This study is to evaluate the effect of food on pharmacokinetics of DA-5222 in healthy adult subjects

Eligibility

Sex
ALL
Min age
19 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria: * Healthy volunteers * BMI between 18 and 30 kg/m2 * Body weight: Male≥50kg, Female≥45kg * Subjects who have signed an informed consent themselves after receiving detailed explanation about clinical study Exclusion Criteria: * Subjects with clinically significant medical history * Subjects with history of drug abuse or addicted * Subjects with allergy or drug hypersensitivity

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Bumin Hospital Seoul South Korea

More Dong-A ST Co., Ltd. trials in South Korea

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06993168 on ClinicalTrials.gov ↗ ← All trials in South Korea